Charles Schwab Investment Management Inc. Raises Stake in Novo Nordisk A/S (NYSE:NVO)

Charles Schwab Investment Management Inc. increased its stake in Novo Nordisk A/S (NYSE:NVOFree Report) by 38.1% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 94,544 shares of the company’s stock after buying an additional 26,067 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Novo Nordisk A/S were worth $9,781,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. CNB Bank bought a new stake in Novo Nordisk A/S in the 4th quarter valued at about $26,000. Pacific Center for Financial Services raised its position in shares of Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the period. Valued Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $28,000. Bell Investment Advisors Inc raised its position in shares of Novo Nordisk A/S by 79.9% in the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares during the period. Finally, Tyler Stone Wealth Management raised its position in shares of Novo Nordisk A/S by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after purchasing an additional 146 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $132.80 on Friday. The firm’s 50 day simple moving average is $128.43 and its 200 day simple moving average is $117.36. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $595.94 billion, a PE ratio of 45.79, a price-to-earnings-growth ratio of 1.39 and a beta of 0.43. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.06. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. The business had revenue of $9.52 billion during the quarter, compared to analysts’ expectations of $9.23 billion. As a group, analysts expect that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target on the stock. The Goldman Sachs Group initiated coverage on shares of Novo Nordisk A/S in a research report on Thursday. They issued a “buy” rating and a $156.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $137.33.

Read Our Latest Research Report on Novo Nordisk A/S

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Featured Stories

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.